Supplemental Digital Content is available in the text
flow cytometry, in relation to clinical parameters and previously established LN classes assessed according to the ISN/RPS 2003 classification. Results Lymphocytes percentages in class IV were different from classes III, V or a combination of III and V. In the latter classes, the percentages of the Tregs and Th17 cells were significantly lower, whereas in class IV the increase in FOXP3 in the Tregs and Th17 cells over six months period was significantly higher (Table 1). Changes in glomerular filtration rate and SLEDAI within 5 years did not correlate with single or repeated Tregs measurements. Conclusions Differences in lymphocyte proportions between class IV and other classes may suggest its distinct pathogenesis and warrants further investigations on their role as LN biomarker.
BackgroundSince more common patterns of antinuclear antibodies (ANAs) such as homogeneous or nucleolar patterns are well recognized, the prevalence of uncommon or atypical pattern is not well describedObjectivesOur aim was to describe the prevalence of atypical ANAs patterns in a big cohort of ANA measurements in general Colombian population.MethodsWe included all ANAS determinations done during 2 consecutive years (2013 and 2014) from Dinamica IPS in 8 different cities in Colombia. We defined such as uncommon patters the following: anti MSA-2 (mitotic spindle apparatus), cytoplasmatic fibers, lysosomal, Golgi, multiple dots, NuMA1 (MSA-1), anti MSA-3, PCNA, centrosome and nuclear envelope. All patient sera submitted for ANAs testing were tested by conventional indirect immunofluorescence using Hep-2 cells (AESKU.DIAGNOSTICS, Wendelsheim, Germany). We use 3 images for sample and in some cases several dilutions were needed. Parametric test were used for comparison among groups.ResultsThe overall sample included 113,491 consecutive samples for ANAs, being positive in 62,501 (55%) cases. 912 (1.45%) samples in 838 patients were classified as atypical pattern. Mean age for atypical positive pattern patients was 47±16.8 years and 80% of patients were female. The most common atypical patterns are summarized in Table. We did not find any difference among sex according atypical patterns. In subgroup analysis, centrosome pattern was more common in younger patients (<18 years) than in older than 18 years (27.84% vs 11.5%; Chi2, p=0.001), anti MSA-2 pattern was significantly more common in patients >18 years than in ≤18 years (23.6% vs 11.3%; Chi2, p=0.038), and cytoplasmic fibers was more prevalent in patients older than 55 years (14.7 vs 9%, p=0.013).Table 1.More common atypical ANA patterns in Colombian populationN=843%NuMA29435.0Midbody (MSA-2)19022.5Centriosome10612.5Cytoplasmatic fibers9311.0Multiple dots829.7Lysosomal283.3Golgi212.5PCNA192.3MSA-381.0Nuclear envelope20.2ConclusionsIn this large cohort of almost 130.000 samples of ANAs from a Colombian general population, the prevalence of atypical ANAs was around 1.5%. That prevalence is in concordance with some other series (1). Anti NuMa and MSA-2 patterns were the most common atypical ANAS. Anti centrosome were more common in young people, anti MSA in middle age patients and anti cytoplasmic fibers in elderly population.ReferencesVermeersch P et al. Autoimmunity Rev 2013;12:998–1003Disclosure of InterestNone declared
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.